Catalyst

Slingshot members are tracking this event:

Arvinas (ARVN) & Pfizer (PFE) announce update on Phase 1 dose escalation data of ARV-471 in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ARVN

100%
PFE

100%

Additional Information

Clinical Data
  • ARV-471 demonstrated antitumor activity in CDK4/6 inhibitor-pretreated patients with a clinical benefit rate (CBR) of 40% in 47 evaluable patients. This heavily pretreated patient group had a median of four prior therapies.
  • Three patients exhibited confirmed partial responses (PR) among the 38 patients with response evaluation criteria in solid tumors (RECIST) measurable lesions and at least one on-treatment tumor assessment.
  • ARV-471 continues to demonstrate a favorable tolerability profile. Robust ER degradation was observed at all dose levels, reaching 89% reduction of ER.
https://ir.arvinas.c...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 10, 2021
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Arv-471, Her2- Metastatic Breast Cancer